Welcome to our dedicated page for Jin Medical news (Ticker: ZJYL), a resource for investors and traders seeking the latest updates and insights on Jin Medical stock.
Jin Medical International Ltd. reports developments tied to its rehabilitation medical equipment business, including wheelchair and living-aid products for people with disabilities, elderly users and rehabilitation applications. The company designs, develops, manufactures and markets mobility products, with wheelchair models sold through distributors in China, Japan and other international markets.
Recurring news for ZJYL includes updates on manufacturing capacity in China, including the Chuzhou facility and Class I Medical Device production licensing, as well as management communications on strategy and capital structure. Company announcements also cover Nasdaq listing compliance, the completed share combination, and the reclassification of ordinary shares into Class A and Class B ordinary shares.
Jin Medical International (NASDAQ: ZJYL) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement. The Company restored compliance after its Class A ordinary shares maintained a closing bid of at least $1.00 per share for more than ten consecutive business days. The Company said it will continue focusing on core operations and ongoing strategic initiatives.
Jin Medical International (NASDAQ: ZJYL) announced a 1-for-20 share combination and share class reclassification effective March 16, 2026 at 09:00 a.m. ET. The reclassification creates 45,000,000 Class A and 5,000,000 Class B authorized shares (par value US$0.001).
Issued Class A shares will consolidate from 136,547,100 to 6,827,355 and Class B from 20,000,000 to 1,000,000; new Class A CUSIP is G5140V120. The company says the move aims to support Nasdaq continued-listing compliance and strengthen long-term capital structure.
Jin Medical (NASDAQ:ZJYL) hosted a CEO Fireside Chat on February 2, 2026 outlining strategic priorities and operational plans. Key points: board-authorized reverse split proposal, 2026–2027 focus on commercialization after product certifications, manufacturing scale-up, cost normalization, and regional/international expansion.
The company said its Chuzhou factory is expected to reach full capacity by end of April 2026 and will support automation, lower unit costs, and tighter quality control as part of disciplined capital allocation.
Jin Medical International (NASDAQ: ZJYL) will host a management fireside chat on Feb 1, 2026 at 8:00 PM EST, led by the CEO and the management team. The discussion will cover the company's recent strategic priorities and long-term growth considerations. The event will be webcast on the company's updated corporate website at http://www.jinmed.com. Investors can view the live webcast on the site for direct comments from management and insight into the company’s strategic direction.
Jin Medical (NASDAQ: ZJYL) announced its Chuzhou, Anhui manufacturing facility achieved final construction milestones and regulatory clearance for Class I medical device production on Dec 29, 2025. The company projects to begin full-capacity production by the end of April 2026, with an annual capacity of 200,000 units of mid-to-high-end electric wheelchairs and senior mobility scooters.
Located in the Yangtze River Delta, the facility will use automated lines to improve cost control, product quality, and supply-chain resilience, supporting domestic and international demand for assistive devices.
Jin Medical International (NASDAQ: ZJYL) said members of its management team will host a fireside chat on February 1, 2026 to discuss the company’s strategic priorities and capital structure considerations.
The session will cover recent market developments, the framework of ongoing strategic planning, and management’s decision-making approach. Management stated it believes the company has a strong liquidity position and is evaluating a range of strategic options to enhance competitive positioning.
Jin Medical International (NASDAQ:ZJYL) has launched production at Plant No. 3 of its intelligent manufacturing facility in Chuzhou, Anhui, China. The state-of-the-art facility features robotic arms and temperature-controlled workshops with an annual production capacity of 200,000 units.
The company, leveraging 19 years of rehabilitation technology expertise, manufactures various products including ultra-light wheelchairs, Paralympic-certified competition equipment, micro hyperbaric oxygen chambers, and beauty devices. The facility meets Japanese Industrial Standards (JIS) certification requirements and is preparing to supply electric wheelchairs to markets in Istanbul, Jerusalem, and Tokyo.
Jin Medical International (NASDAQ: ZJYL) has received a deficiency notice from Nasdaq on May 2, 2025, due to non-compliance with the minimum bid price requirement. The company's stock price remained below $1.00 for 30 consecutive business days between March 20 and May 1, 2025. ZJYL has been granted a 180-day compliance period until October 29, 2025, to regain compliance by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive business days.
If unsuccessful, the company may be eligible for an additional 180-day period, provided it meets other Nasdaq Capital Market listing requirements. Options for compliance include implementing a reverse stock split. Failure to meet requirements could result in delisting from Nasdaq.
JIN MEDICAL INTERNATIONAL (NASDAQ: ZJYL), a leader in Assistive Technologies (AT) and manufacturer of wheelchairs and living aids, has announced the start of construction for its new manufacturing facility in Chuzhou City, Anhui Province, China. The facility, operated by JinMed (Anhui) Co., , will be an internationally standardized, innovative, and high-end wheelchair manufacturing plant.
The new facility is expected to strengthen JinMed's position in the AT industry with higher-level production lines and more innovative products. Targeted to operate in 2025, it will expand capacity for manual wheelchairs and introduce production lines for electric wheelchairs, electric scooters, micro hyperbaric chambers, and scientific cosmetic products.
CEO Wang Erqi stated that this development marks a major milestone for JinMed, aligning with their goal of 'global technology for the benefit of mankind' and demonstrating the company's commitment to industry leadership.
Summary not available.